Reuters logo
BRIEF-Peregrine Pharma up in premarket after internal review of phase II lung cancer trial
January 7, 2013 / 1:50 PM / in 5 years

BRIEF-Peregrine Pharma up in premarket after internal review of phase II lung cancer trial

NEW YORK, Jan 7 (Reuters) - Peregrine Pharmaceuticals Inc : * Peregrine Pharma up 31.1 percent to $1.77 in premarket after an update of its internal review of the phase II second-line non-small call lung cancer trial

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below